Advertisement

Topics

Actuate Therapeutics Secures $21.7 Million to Support Phase I/II Clinical Trial

20:00 EDT 16 May 2019 | BioSpace

The company took its GSK-3B inhibitor into the clinic earlier this year. The drug is being studied in patients with refractory hematologic malignancies or solid tumors.

Original Article: Actuate Therapeutics Secures $21.7 Million to Support Phase I/II Clinical Trial

NEXT ARTICLE

More From BioPortfolio on "Actuate Therapeutics Secures $21.7 Million to Support Phase I/II Clinical Trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...